Trenton, NJ — In partnership with J.P. Morgan, BioNJ will host its Seventh Annual BioPartnering Conference on Tuesday, May 23, 2017, from 8:00 a.m. to 5:00 p.m. at the Busch Campus Center at Rutgers University in Piscataway.
The event is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions.
“We’re thrilled to be partnering with J.P. Morgan on this year’s BioPartnering Conference,” said Debbie Hart, President and CEO, BioNJ.
“With valuable insights from J.P. Morgan, the agenda will dive into the marketplace issues, challenges and trends that are impacting deal making, financial viability and the opportunity for medical innovation,” Hart added.
The event is expected to bring together over 200 regional biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of networking, 1-1 partnering meetings, company presentations, exhibits and plenary sessions.
“We’re thrilled to be partnering with J.P. Morgan on this year’s BioPartnering Conference,” said Debbie Hart, President and CEO, BioNJ.
“With valuable insights from J.P. Morgan, the agenda will dive into the marketplace issues, challenges and trends that are impacting deal making, financial viability and the opportunity for medical innovation,” Hart added.
Sharing their perspectives will be J.P. Morgan executives.
Robert Huffines, Vice Chairman of Healthcare Banking, will kick off the day with an industry update and trends overview
Mr. Huffines joined J.P. Morgan in 1991 in the M&A group where he was healthcare focused. From 2002-2010, he was Co-Head of the Global Healthcare Investment Banking Group and later was promoted to Vice Chairman in 2011. In 2017, he was added to the Global Banking Management Team and named Co-Chair of the Global Strategic Advisory Council.
Philip Ross, M.D., Managing Director Healthcare Investment Banking Group, will moderate a panel to discuss capital raising and what now constitutes an attractive investment
As a client executive and key coverage partner in Healthcare Investment Banking, Dr. Ross is responsible for relationships with many of J.P. Morgan’s clients in the biotechnology industry. He also leverages his biotechnology expertise for J.P. Morgan’s global pharmaceutical coverage effort.
Michael Griffin, Managing Director and Investment Specialist, will lead a fireside chat with an industry research analyst
In his current role, Mr. Griffin is responsible for advising ultra-high net worth individuals, foundations and senior executives on a range of financial matters including asset allocation, portfolio construction, equities, fixed income and alternative investments.
Alma DeMetropolis, President, New Jersey Market Leadership Team and Senior Investment Specialist, will wrap up with a regional note and the day’s insights around navigating the evolving marketplace dynamics
Ms. DeMetropolis has been advising ultra-high net worth individuals, families, endowments and foundations on a broad range of wealth matters and managing investment portfolios for over 20 years and has been with J.P. Morgan for over 25 years. She is actively involved in leading the bank’s initiatives across New Jersey.
Joining this year’s exhibits will be industry liaisons from Rutgers University, Princeton University, University of Pennsylvania and New York University among other regional university research centers.
“Throughout the day, R&D companies will showcase their technologies and business models before an All-Star Panel of Judges,” added Hart. “It’s all about growing the ecosystem and bolstering opportunity for medical innovation.”
Apply by April 15 to be a company presenter. Limited presentation slots available.
Register by April 14 for the Early Bird rate of $250 for BioNJ, LES and NewYorkBIO Members and $300 for Future Members.
Contact Edie Esposito at 609-890-3185 or EEsposito@BioNJ.org to discuss exhibit and sponsorship opportunities. Visit www.BioNJ.org to learn more.
BioNJ thanks its sponsors: Amicus Therapeutics; Ashton Tweed; ContraVir Pharmaceuticals; Dynamic Strategies; EisnerAmper; Fisher Scientific; Friedman LLP; Johnson & Johnson; Merck & Co.; New Jersey Health Foundation; Law Office of Philip P. Crowley LLC; Princeton University; Rutgers, The State University of New Jersey and ThromboGenics.
About BioNJ
BioNJ, The Gateway to Health, is a network of 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources.
For more information about BioNJ, please visit www.BioNJ.org.
Robert Huffines, Vice Chairman of Healthcare Banking, will kick off the day with an industry update and trends overview
Mr. Huffines joined J.P. Morgan in 1991 in the M&A group where he was healthcare focused. From 2002-2010, he was Co-Head of the Global Healthcare Investment Banking Group and later was promoted to Vice Chairman in 2011. In 2017, he was added to the Global Banking Management Team and named Co-Chair of the Global Strategic Advisory Council.
Philip Ross, M.D., Managing Director Healthcare Investment Banking Group, will moderate a panel to discuss capital raising and what now constitutes an attractive investment
As a client executive and key coverage partner in Healthcare Investment Banking, Dr. Ross is responsible for relationships with many of J.P. Morgan’s clients in the biotechnology industry. He also leverages his biotechnology expertise for J.P. Morgan’s global pharmaceutical coverage effort.
Michael Griffin, Managing Director and Investment Specialist, will lead a fireside chat with an industry research analyst
In his current role, Mr. Griffin is responsible for advising ultra-high net worth individuals, foundations and senior executives on a range of financial matters including asset allocation, portfolio construction, equities, fixed income and alternative investments.
Alma DeMetropolis, President, New Jersey Market Leadership Team and Senior Investment Specialist, will wrap up with a regional note and the day’s insights around navigating the evolving marketplace dynamics
Ms. DeMetropolis has been advising ultra-high net worth individuals, families, endowments and foundations on a broad range of wealth matters and managing investment portfolios for over 20 years and has been with J.P. Morgan for over 25 years. She is actively involved in leading the bank’s initiatives across New Jersey.
Joining this year’s exhibits will be industry liaisons from Rutgers University, Princeton University, University of Pennsylvania and New York University among other regional university research centers.
“Throughout the day, R&D companies will showcase their technologies and business models before an All-Star Panel of Judges,” added Hart. “It’s all about growing the ecosystem and bolstering opportunity for medical innovation.”
Apply by April 15 to be a company presenter. Limited presentation slots available.
Register by April 14 for the Early Bird rate of $250 for BioNJ, LES and NewYorkBIO Members and $300 for Future Members.
Contact Edie Esposito at 609-890-3185 or EEsposito@BioNJ.org to discuss exhibit and sponsorship opportunities. Visit www.BioNJ.org to learn more.
BioNJ thanks its sponsors: Amicus Therapeutics; Ashton Tweed; ContraVir Pharmaceuticals; Dynamic Strategies; EisnerAmper; Fisher Scientific; Friedman LLP; Johnson & Johnson; Merck & Co.; New Jersey Health Foundation; Law Office of Philip P. Crowley LLC; Princeton University; Rutgers, The State University of New Jersey and ThromboGenics.
About BioNJ
BioNJ, The Gateway to Health, is a network of 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount.
Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources.
For more information about BioNJ, please visit www.BioNJ.org.
